These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 3298138)
1. Adriamycin: review of clinical pharmacology and toxicity of an effective anticancer drug. Riggs CE; Sharp SA Iowa Med; 1987 May; 77(5):242, 245-51. PubMed ID: 3298138 [No Abstract] [Full Text] [Related]
2. [Adriamycin cardiomyopathy]. Nilles M; Wehr M; Köhler F Med Welt; 1984 Jan; 35(4):103-8. PubMed ID: 6700420 [No Abstract] [Full Text] [Related]
3. [The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy]. Katamadze NA; Lartsuliani KP; Begishvili NN; Dundua KhV; Kiknadze MP Georgian Med News; 2006 Jan; (130):61-4. PubMed ID: 16510915 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. Miller AA; Schmidt CG Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348 [TBL] [Abstract][Full Text] [Related]
5. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. Synold TW; Doroshow JH J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin (Adriamycin)--a new anticancer drug. Med Lett Drugs Ther; 1975 May; 17(10):42-3. PubMed ID: 1055286 [No Abstract] [Full Text] [Related]
7. [Cardiotoxicity of doxorubicin in children]. Pilon JW; Naeff MS; Taminiau JA Ned Tijdschr Geneeskd; 1984 Jul; 128(28):1339-43. PubMed ID: 6482993 [No Abstract] [Full Text] [Related]
8. [A phase I study of 4'-epi-adriamycin, a new anthracycline anticancer agent]. Kimura K; Wakui A; Saito T; Tominaga T; Niitani H; Fujimoto T; Masaoka T; Toki H; Tamura K Gan To Kagaku Ryoho; 1984 Nov; 11(11):2414-9. PubMed ID: 6594078 [TBL] [Abstract][Full Text] [Related]
9. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Outomuro D; Grana DR; Azzato F; Milei J Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672 [TBL] [Abstract][Full Text] [Related]
11. Dilated cardiomyopathy in a pregnant woman after doxorubicin and radiotherapy for Hodgkin's disease: a case report. Hadar A; Sheiner E; Press F; Katz A; Katz M J Reprod Med; 2004 May; 49(5):401-3. PubMed ID: 15214719 [TBL] [Abstract][Full Text] [Related]
12. [Cardiac toxicity in cancer therapy]. Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515 [TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836 [TBL] [Abstract][Full Text] [Related]
16. A phase of I trial of 4'-epi-Adriamycin. Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126 [TBL] [Abstract][Full Text] [Related]
17. [Clinical pharmacology of doxorubicin (adriamycin)]. Drzewoski J; Matusewicz W Pol Tyg Lek; 1982 Sep; 37(36):1071-3. PubMed ID: 7170261 [No Abstract] [Full Text] [Related]
18. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Hurteloup P; Ganzina F Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075 [TBL] [Abstract][Full Text] [Related]